The Role of Biomarkers and Echocardiography in Prediction of Prognosis of Chronic Heart Failure Patients (Bio-SHiFT)
Serial Biomarker Measurements and New Echocardiographic Techniques in Chronic Heart Failure Patients Result in Tailored Prediction of Prognosis
The Bio-SHiFT study aims to investigate whether disease progression in individual patients with chronic heart failure (CHF) can be accurately assessed by serial measurements of disease-related (novel) biomarkers. Secondary objectives of the study include comparison of 2D- with real-time 3D-echocardiography in CHF patients and comparison of Speckle tracking with tissue Doppler imaging (TDI) in CHF patients, and relating these echocardiographic measurements to clinical outcome.
Bio-SHiFT is a prospective, observational, multi-center, cohort study in men and women, aged 18 years or older, visiting the outpatient clinic. Blood samples are taken at the day of inclusion and at follow-up visits, which are performed every 3 months until the end of the scheduled follow-up. Clinical data are collected at baseline and at each 3-month follow-up visit. Echocardiography including TDI, Speckle tracking and 3D-echocardiography is performed in a subset of patients, at baseline and during follow-up at 6-month intervals. The primary endpoint is the composite of cardiovascular death, cardiac transplantation, left ventricular assist device implantation, and re-hospitalization for the management of acute or worsened heart failure.
調査の概要
研究の種類
入学 (実際)
連絡先と場所
研究場所
-
-
-
Alkmaar、オランダ
- Medical Center Alkmaar
-
Rotterdam、オランダ
- Erasmus MC
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
説明
Inclusion Criteria:
- Men and women, aged 18 years or older, capable of understanding and signing informed consent
- Diagnosis of chronic heart failure (with diminished ejection fraction or with normal ejection fraction), according to the guidelines of the European Society of Cardiology (ESC)
Exclusion Criteria:
- Heart failure secondary to circulatory high output conditions
- Scheduled for surgery or intervention for both coronary and non-coronary indication
- Severe renal failure for which dialysis is needed
- Known moderate or severe liver disease
- Chronic Obstructive Pulmonary Disease (COPD) Gold stage IV
- Congenital heart disease
- Coexistent condition with life expectancy ≤ 1 year
- Unlikely to appear at all scheduled follow-up visits
- Linguistic barrier
研究計画
研究はどのように設計されていますか?
デザインの詳細
コホートと介入
グループ/コホート |
介入・治療 |
---|---|
Chronic heart failure patients visiting the outpatient clinic
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
時間枠 |
---|---|
The composite of cardiovascular death, cardiac transplantation, left ventricular assist device implantation, and re-hospitalization for the management of acute or worsened heart failure.
時間枠:maximum follow-up is 2.5 years
|
maximum follow-up is 2.5 years
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
Cardiovascular death
時間枠:maximum follow-up is 2.5 years
|
maximum follow-up is 2.5 years
|
|
Cardiac transplantation
時間枠:maximum follow-up is 2.5 years
|
maximum follow-up is 2.5 years
|
|
Left ventricular assist device implantation
時間枠:maximum follow-up is 2.5 years
|
maximum follow-up is 2.5 years
|
|
Re-hospitalization for acute or worsened heart failure
時間枠:maximum follow-up is 2.5 years
|
maximum follow-up is 2.5 years
|
|
Cardiovascular disease: myocardial infarction (fatal and non-fatal), stroke (fatal and non-fatal), percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG)
時間枠:maximum follow-up is 2.5 years
|
Cardiovascular disease, comprising all events specified above, will be examined, as well as all individual components.
|
maximum follow-up is 2.5 years
|
All-cause mortality
時間枠:maximum follow-up is 2.5 years
|
maximum follow-up is 2.5 years
|
協力者と研究者
スポンサー
捜査官
- スタディチェア:Eric Boersma, MSc, PhD、Erasmus Medical Center
- スタディディレクター:Isabella Kardys, MD, PhD、Erasmus Medical Center
- 主任研究者:Victor Umans, MD, PhD、Medical Center Alkmaar
- 主任研究者:Martijn Akkerhuis, MD, PhD、Erasmus Medical Center
出版物と役立つリンク
一般刊行物
- Klimczak-Tomaniak D, de Bakker M, Bouwens E, Akkerhuis KM, Baart S, Rizopoulos D, Mouthaan H, van Ramshorst J, Germans T, Constantinescu A, Manintveld O, Umans V, Boersma E, Kardys I. Dynamic personalized risk prediction in chronic heart failure patients: a longitudinal, clinical investigation of 92 biomarkers (Bio-SHiFT study). Sci Rep. 2022 Feb 18;12(1):2795. doi: 10.1038/s41598-022-06698-3.
- Bouwens E, Schuurman AS, Akkerhuis KM, Manintveld OC, Caliskan K, van Ramshorst J, Germans T, Umans VA, Boersma E, Kardys I. Associations of serially measured PCSK9, LDLR and MPO with clinical outcomes in heart failure. Biomark Med. 2021 Mar;15(4):247-255. doi: 10.2217/bmm-2020-0585. Epub 2021 Feb 16.
- Bouwens E, Brankovic M, Mouthaan H, Baart S, Rizopoulos D, van Boven N, Caliskan K, Manintveld O, Germans T, van Ramshorst J, Umans V, Akkerhuis KM, Kardys I. Temporal Patterns of 14 Blood Biomarker candidates of Cardiac Remodeling in Relation to Prognosis of Patients With Chronic Heart Failure-The Bio- SH i FT Study. J Am Heart Assoc. 2019 Feb 19;8(4):e009555. doi: 10.1161/JAHA.118.009555.
研究記録日
主要日程の研究
研究開始
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。
心不全の臨床試験
-
Novartis Pharmaceuticals完了EC-MPS による治療に関心があり、コア研究の 12 か月の治療期間を無事に完了した患者 (de novo Heart Recipients)
Observational study; no intervention.の臨床試験
-
University of California, San FranciscoSan Francisco Veterans Affairs Medical Center; Tobacco Related Disease Research Program完了